Key takeaways
- Retatrutide, a triple-hormone agonist, has shown up to 25% weight loss in clinical trials.
- Cagrilintide, an amylin analog, is being developed in combination with semaglutide as CagriSema.
- Tirzepatide and semaglutide are FDA-approved for weight loss and diabetes treatment.
- Research on these peptides is ongoing, with more studies needed to fully understand their effects.
Recent studies have highlighted the potential of peptides in treating weight loss and diabetes. Semaglutide and Tirzepatide are already FDA-approved for these conditions, while Retatrutide and Cagrilintide are still in development.
Retatrutide's phase 3 weight-loss numbers
{{retatrutide}} Retatrutide has shown significant weight loss in clinical trials, with some participants achieving up to 25% weight loss. This is a promising result, especially considering the limited treatment options available for obesity. The TRIUMPH-1 trial, published in the New England Journal of Medicine, demonstrated the efficacy of retatrutide in treating obesity.
Cagrilintide's development as CagriSema
{{cagrilintide}} Cagrilintide is being developed in combination with semaglutide as CagriSema. This combination therapy has shown potential in treating obesity and diabetes, with a recent study published in Diabetes, Obesity and Metabolism demonstrating its efficacy in reaching anthropometric treatment targets and improving cardiometabolic outcomes.
Comparison of peptides
| Peptide | What it is | FDA status | Evidence | Half-life | Banned in sport |
|---|---|---|---|---|---|
| Retatrutide | Triple-hormone agonist | Not FDA-approved | 4 | 6 days | No |
| Tirzepatide | Dual GIP/GLP-1 agonist | FDA-approved | 5 | 5 days | No |
| Semaglutide | GLP-1 receptor agonist | FDA-approved | 5 | 7 days | No |
| Cagrilintide | Amylin analog | Not FDA-approved | 4 | 7-8 days | No |
The bottom line
While these peptides show promise in treating weight loss and diabetes, more research is needed to fully understand their effects. It's essential to consult with a healthcare professional before considering any treatment options.
This is educational information, not medical advice.
Sources
No sources were cited.